Alemtuzumab is a monoclonal antibody. It flags the cancer cells for destruction by the body's immune system. It also modulates the immune system to limit its attacks on the nervous system.
Rash, Headache, Insomnia (difficulty in sleeping), Nausea, Upper respiratory tract infection, Decreased white blood cell count, Fatigue, Fever, Itching, Flushing (sense of warmth in the face, ears, neck and trunk), Urticaria, Decreased white blood cell count (lymphocytes)
Alemtuzumab is used in the treatment of blood cancer (Chronic lymphocytic leukemia) and multiple sclerosis (MS).
Yes, Alemtuzumab is FDA approved for Multiple sclerosis